

Appl. No. 09/825,423
Response dated November 28, 2006
Reply to Office Action of October 3, 2006

Patent Case: ID01152

- 2 -

RECEIVED
CENTRAL FAX CENTER

NOV 28 2006

Amendment to the Claims

The listing of claims will replace all prior versions of claims in the application:

Claim 1 (previously presented): An isolated polypeptide defined by the amino acid sequence set forth in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 17.

Claim 2 (previously presented): The polypeptide of claim 1, defined by the amino acid sequence set forth in SEQ ID NO: 17.

Claim 3 (previously presented): The polypeptide of claim 1, defined by the amino acid sequence set forth in SEQ ID NO: 3.

Claim 4-6 (cancelled).

Claim 7 (previously presented): The polypeptide of claim 1, defined by the amino acid sequence set forth in SEQ ID NO: 5.

Claim 8 (previously presented): The polypeptide of claim 1, defined by the amino acid sequence set forth in SEQ ID NO: 6.

Claim 9 (currently amended): An isolated polypeptide ~~defined by a variant consisting~~ of the amino acid sequence set forth in SEQ ID NO: 3, SEQ ID NO: 5, ~~and or~~ SEQ ID NO: 6 except that the polypeptide has, wherein the variant consists of a single amino acid substitution at Asp 73 or Arg 81, and wherein the substitution is a nonpolar amino acid.

Claim 10 (cancelled)

Claim 11 (currently amended): A ~~crystalline~~ composition, comprising a protein crystal of an isolated polypeptide defined by the amino acid sequence set forth in SEQ ID NO: 17, wherein the crystal has space group P21 and unit cell dimensions of a=34.8 Å, b=67.1 Å, c=58.4 Å, α=90°, β=101.3°, γ=90° with two molecules of SEQ ID NO:17 in the asymmetric unit and the structural coordinates set forth in Table 5.

71661_1.DOC

Appl. No. 09/825,423
Response dated November 28, 2006
Reply to Office Action of October 3, 2006

Patent Case: ID01152

- 3 -

Claims 12-20 (cancelled).

Claim 21 (currently amended): An isolated polypeptide defined by a ~~variant~~ consisting of the amino acid sequence set forth in SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 6, except that the polypeptide has ~~wherein the variant consists of~~ a single amino acid substitution at Asp 73 or Arg 81, and wherein the substitution at Asp 73 is lysine or arginine and the substitution at Arg 81 is glutamic acid or aspartic acid.

Claim 22 (currently amended): An isolated polypeptide defined by a ~~variant~~ consisting of the amino acid sequence set forth in SEQ ID NO: 5, except that the polypeptide has ~~wherein the variant consists of~~ a substitution of the amino acids at positions 255-258 with SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, or 14.

71661_1.DOC